Baxter (NYSE:BAX) said yesterday that it won CE Mark approval in the European Union for its Homechoice Claria device, a designed for automated home peritoneal dialysis treatments.
The Claria device provides a secure, 2-way connection between the end-stage renal failure patient and the physician, Baxter said.
"Claria builds upon our market-leading Homechoice [automated peritoneal dialysis] device with new features to make the system more intuitive for patients to operate in their home and while traveling,” renal vice president Dr. Bruce Culleton said in prepared remarks. “Additionally, Sharesource, the system’s web-based platform, provides physicians remote access to their home patients’ treatment information allowing for more timely and personalized care.”
Baxter said it plans to launch Homechoice Claria in "select" European and Asian markets during the 1st half of this year.
“Every patient with end-stage renal disease deserves access to individualized care,” renal president Jill Schaaf added. “Homechoice Claria with Sharesource represents Baxter’s continued commitment to advancing renal technology that offers healthcare providers and patients therapy options for end-stage renal disease.”
